Cotempla Xr-odt Tablet, Orally Disintegrating
NDC Package 70165-100-30
Package Information
Cotempla Xr-odt (methylphenidate) tablets is cOTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age [see Clinical Studies (14)]. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Neos Therapeutics Brands, Llc, this product is identified by NDC 70165-100 and is authorized under FDA application NDA205489.
Identification & Billing
- RxCUI: 1926840 - methylphenidate 17.3 MG Extended Release Disintegrating Oral Tablet
- RxCUI: 1926840 - methylphenidate 17.3 MG Disintegrating Oral Tablet
- RxCUI: 1926847 - Cotempla XR-ODT 17.3 MG Extended Release Disintegrating Oral Tablet
- RxCUI: 1926847 - methylphenidate 17.3 MG Disintegrating Oral Tablet [Cotempla]
- RxCUI: 1926847 - Cotempla 17.3 MG Disintegrating Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70165 - Neos Therapeutics Brands, Llc
- 70165-100 - Cotempla Xr-odt
- 70165-100-30 - 5 BLISTER PACK in 1 CARTON / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
- 70165-100 - Cotempla Xr-odt
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70165-100). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70165-100-30 identifies a specific commercial package of 5 blister pack in 1 carton / 6 tablet, orally disintegrating in 1 blister pack of Cotempla Xr-odt, a human prescription drug labeled by Neos Therapeutics Brands, Llc. This tablet, orally disintegrating is formulated for oral use and contains methylphenidate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Neos Therapeutics Brands, Llc on June 20, 2017. The current certification is valid through December 31, 2027.
How is this Neos Therapeutics Brands, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70165010030. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.